Genc Hasanaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Genc Hasanaj has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Keeser
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich
7 shared publications - Lukas Roell
Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia
7 shared publications - Peter Falkai
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
7 shared publications - Andrea Schmitt
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
6 shared publications - Berkhan Karsli
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich
6 shared publications - Emanuel Boudriot
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
6 shared publications
Latest Publications
- Open Access
Excitation-Inhibition Balance in Schizophrenia Spectrum Disorders: EEG Criticality Reflects Frontal Metabolites and a Potential Compensatory Mechanism
Background The excitation-inhibition (E-I) balance is essential for normal brain functioning, while deviations from this balance have been implicated in several psychiatric disorders. However, the extent to which electroencephalography (EEG) and proton magnetic resonance spectroscopy (1H-MRS) E-I markers are altered in schizophrenia spectrum disorders (SSD), how they converge across modalities, and how they relate to cognitive performance and clinical symptoms remain insufficiently characterized. Methods We recruited 111 healthy controls (HC) and 113 individuals with SSD. All participants underwent resting-state EEG and 1H-MRS. Metabolites were measured either in the anterior cingulate cortex (ACC; NSSD = 63, NHC = 58) or in the left dorsolateral prefrontal cortex (lDLPFC; NSSD = 50, NHC = 53), from which gamma-aminobutyric acid (GABA), glutamate + glutamine (Glx), and the Glx/GABA ratio were extracted. Extracted EEG E-I markers included oscillatory activity, aperiodic activity, functional E-I, microstates, multiscale entropy, and neuronal avalanche criticality. Results MRS results showed no group differences in GABA, Glx, or the Glx/GABA ratio. In contrast, most EEG-derived E-I markers indicated increased cortical inhibition in SSD, including steeper aperiodic exponents, prolonged microstate durations, and greater prevalence of subcritical states. However, functional E-I showed a divergent pattern, suggesting balanced dynamics in SSD and relatively inhibition-weighted dynamics in HC. Across groups, higher ACC and lDLPFC GABA predicted a lower kappa index, whereas a higher lDLPFC Glx/GABA ratio was associated with a higher kappa index. In SSD, reduced avalanche criticality was associated with better cognition and less severe symptoms. Conclusion Several EEG-derived E-I proxies, but not MRS measures, indicate an increased cortical inhibition in SSD. Criticality indices best capture frontal neurochemical metabolites and improvements in clinical symptoms, potentially reflecting inhibitory compensation mechanisms in SSD.
Open AccessExcitation-Inhibition Balance in Schizophrenia Spectrum Disorders: EEG Criticality Reflects Frontal Metabolites and a Potential Compensatory Mechanism
Background The excitation-inhibition (E-I) balance is essential for normal brain functioning, while deviations from this balance have been implicated in several psychiatric disorders. However, the extent to which electroencephalography (EEG) and proton magnetic resonance spectroscopy (1H-MRS) E-I markers are altered in schizophrenia spectrum disorders (SSD), how they converge across modalities, and how they relate to cognitive performance and clinical symptoms remain insufficiently characterized. Methods We recruited 111 healthy controls (HC) and 113 individuals with SSD. All participants underwent resting-state EEG and 1H-MRS. Metabolites were measured either in the anterior cingulate cortex (ACC; NSSD = 63, NHC = 58) or in the left dorsolateral prefrontal cortex (lDLPFC; NSSD = 50, NHC = 53), from which gamma-aminobutyric acid (GABA), glutamate + glutamine (Glx), and the Glx/GABA ratio were extracted. Extracted EEG E-I markers included oscillatory activity, aperiodic activity, functional E-I, microstates, multiscale entropy, and neuronal avalanche criticality. Results MRS results showed no group differences in GABA, Glx, or the Glx/GABA ratio. In contrast, most EEG-derived E-I markers indicated increased cortical inhibition in SSD, including steeper aperiodic exponents, prolonged microstate durations, and greater prevalence of subcritical states. However, functional E-I showed a divergent pattern, suggesting balanced dynamics in SSD and relatively inhibition-weighted dynamics in HC. Across groups, higher ACC and lDLPFC GABA predicted a lower kappa index, whereas a higher lDLPFC Glx/GABA ratio was associated with a higher kappa index. In SSD, reduced avalanche criticality was associated with better cognition and less severe symptoms. Conclusion Several EEG-derived E-I proxies, but not MRS measures, indicate an increased cortical inhibition in SSD. Criticality indices best capture frontal neurochemical metabolites and improvements in clinical symptoms, potentially reflecting inhibitory compensation mechanisms in SSD.
- Open Access
- 23 January 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
The link between GABA levels and P300 abnormalities in schizophrenia spectrum disorders: regional and symptom-based insights
According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms, particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and may contribute to P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P3b subcomponent amplitudes and latencies, cognition, and symptom severity in SSD. In total, 107 patients and 107 healthy controls (HC) were included in the study, with the exact numbers varying across specific analyses. We grouped patients into higher (SSD+, N = 41) and lower (SSD−, N = 65) symptom severity clusters based on PANSS total scores. P3b amplitudes were lower in SSD patients than HC at central and parietal sites. SSD+ exhibited widespread P3b amplitude reductions, significant at parietal and trend-level at central and frontal regions, while SSD− showed a trend-level amplitude reduction limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P3b amplitudes at central and parietal sites within SSD− and overall SSD group. Although P3b amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P3b associations. Our findings suggest P3b amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher illness severity, and that enhanced lDLPFC GABA may contribute to offsetting these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns associated with cognitive dysfunction in SSD.
- 23 January 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
Open AccessThe link between GABA levels and P300 abnormalities in schizophrenia spectrum disorders: regional and symptom-based insights
According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms, particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and may contribute to P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P3b subcomponent amplitudes and latencies, cognition, and symptom severity in SSD. In total, 107 patients and 107 healthy controls (HC) were included in the study, with the exact numbers varying across specific analyses. We grouped patients into higher (SSD+, N = 41) and lower (SSD−, N = 65) symptom severity clusters based on PANSS total scores. P3b amplitudes were lower in SSD patients than HC at central and parietal sites. SSD+ exhibited widespread P3b amplitude reductions, significant at parietal and trend-level at central and frontal regions, while SSD− showed a trend-level amplitude reduction limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P3b amplitudes at central and parietal sites within SSD− and overall SSD group. Although P3b amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P3b associations. Our findings suggest P3b amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher illness severity, and that enhanced lDLPFC GABA may contribute to offsetting these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns associated with cognitive dysfunction in SSD.
- Open Access
From Body to Brain and Back: Multimodal Evidence for Interoceptive Alterations in Schizophrenia Spectrum Disorders
When the brain and body misalign, emotional experience and sense of reality can be disrupted. Although such atypical experiences are central to schizophrenia spectrum disorders (SSD), interoception, processing of internal bodily signals, remains poorly understood in individuals with SSD, particularly across subjective, behavioural, and neural domains. We tested whether SSD is associated with convergent alterations across interoceptive domains and whether these relate to clinical symptoms in a cross-sectional observational design. Patients with SSD ( n = 53) and matched healthy controls (HC; n = 60) completed an EEG experiment comprising eyes-closed and eyes-open resting-state recordings and a heartbeat counting task (HCT), followed by self-report measures. Interoceptive accuracy was derived from the HCT, while cortical responses to afferent cardiac signals were indexed by heartbeat evoked potentials (HEP). In individuals with SSD, subjective interoceptive awareness was altered, characterised by impaired regulation and negative bodily appraisal, alongside elevated depersonalization. At the behavioral level, interoceptive accuracy was marginally lower. HEP positivity was attenuated, most clearly during HCT and, to a lesser extent, in eyes-open rest, over centro-parietal regions, consistent with context-dependent alterations in cortical processing of afferent bodily signals. Symptom–interoception links were largely modest, with depersonalization emerging as the most consistent correlate of clinical severity, suggesting that interoceptive disturbances in SSD may reflect a trait-like, disorder-central alteration. Together, these findings indicate that SSD involves pervasive disturbances in bodily self-experience, marked by impaired interoceptive regulation and by context-dependent neural attenuation during interoceptive engagement. This profile highlights interoceptive dysfunction as a disorder-central feature with potential prognostic and therapeutic relevance.
Open AccessFrom Body to Brain and Back: Multimodal Evidence for Interoceptive Alterations in Schizophrenia Spectrum Disorders
When the brain and body misalign, emotional experience and sense of reality can be disrupted. Although such atypical experiences are central to schizophrenia spectrum disorders (SSD), interoception, processing of internal bodily signals, remains poorly understood in individuals with SSD, particularly across subjective, behavioural, and neural domains. We tested whether SSD is associated with convergent alterations across interoceptive domains and whether these relate to clinical symptoms in a cross-sectional observational design. Patients with SSD ( n = 53) and matched healthy controls (HC; n = 60) completed an EEG experiment comprising eyes-closed and eyes-open resting-state recordings and a heartbeat counting task (HCT), followed by self-report measures. Interoceptive accuracy was derived from the HCT, while cortical responses to afferent cardiac signals were indexed by heartbeat evoked potentials (HEP). In individuals with SSD, subjective interoceptive awareness was altered, characterised by impaired regulation and negative bodily appraisal, alongside elevated depersonalization. At the behavioral level, interoceptive accuracy was marginally lower. HEP positivity was attenuated, most clearly during HCT and, to a lesser extent, in eyes-open rest, over centro-parietal regions, consistent with context-dependent alterations in cortical processing of afferent bodily signals. Symptom–interoception links were largely modest, with depersonalization emerging as the most consistent correlate of clinical severity, suggesting that interoceptive disturbances in SSD may reflect a trait-like, disorder-central alteration. Together, these findings indicate that SSD involves pervasive disturbances in bodily self-experience, marked by impaired interoceptive regulation and by context-dependent neural attenuation during interoceptive engagement. This profile highlights interoceptive dysfunction as a disorder-central feature with potential prognostic and therapeutic relevance.
- Open Access
- 4 October 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (7) , e70263
Periodic and Aperiodic Alterations of Resting‐State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights
Schizophrenia spectrum disorders (SSD) are marked by cognitive deficits and clinical symptoms linked to disrupted neural oscillations. While changes in spectral power are well documented in SSD, many studies have not clearly separated rhythmic (periodic) from the nonrhythmic (aperiodic) brain activity. This study examined both periodic and aperiodic resting‐state EEG components in SSD, recorded from 152 healthy controls and 97 SSD participants. EEG features (periodic power, bandwidth, center frequency; aperiodic exponent and offset) were extracted from global scalp averages and frontoinsular regions, including the dorsal anterior cingulate cortex (dACC), right anterior insula (R‐INS), and left anterior insula (L‐INS). At the scalp level, SSD individuals exhibited a global increase in theta power, along with a decreased alpha center frequency. Aperiodic activity showed increased exponent and offset in SSD. In frontoinsular regions, increased theta power was observed in the dACC, R‐INS, and L‐INS, along with lower alpha center frequency in L‐INS. No significant differences were found for aperiodic activity in these regions. Increased frontoinsular theta power, especially in the dACC, was associated with worse cognitive performance, particularly global cognition and working memory. These findings highlight the importance of separating periodic and aperiodic EEG activity in SSD, suggesting that periodic alterations, particularly in frontoinsular theta oscillations, may underlie cognitive dysfunction in SSD.
- 4 October 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (7) , e70263
Open AccessPeriodic and Aperiodic Alterations of Resting‐State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights
Schizophrenia spectrum disorders (SSD) are marked by cognitive deficits and clinical symptoms linked to disrupted neural oscillations. While changes in spectral power are well documented in SSD, many studies have not clearly separated rhythmic (periodic) from the nonrhythmic (aperiodic) brain activity. This study examined both periodic and aperiodic resting‐state EEG components in SSD, recorded from 152 healthy controls and 97 SSD participants. EEG features (periodic power, bandwidth, center frequency; aperiodic exponent and offset) were extracted from global scalp averages and frontoinsular regions, including the dorsal anterior cingulate cortex (dACC), right anterior insula (R‐INS), and left anterior insula (L‐INS). At the scalp level, SSD individuals exhibited a global increase in theta power, along with a decreased alpha center frequency. Aperiodic activity showed increased exponent and offset in SSD. In frontoinsular regions, increased theta power was observed in the dACC, R‐INS, and L‐INS, along with lower alpha center frequency in L‐INS. No significant differences were found for aperiodic activity in these regions. Increased frontoinsular theta power, especially in the dACC, was associated with worse cognitive performance, particularly global cognition and working memory. These findings highlight the importance of separating periodic and aperiodic EEG activity in SSD, suggesting that periodic alterations, particularly in frontoinsular theta oscillations, may underlie cognitive dysfunction in SSD.
- Open Access
Modulating Brain Perfusion, Functional Connectivity, and Metabolite Patterns through Theta Burst Transcranial Ultrasonic Stimulation
Background Transcranial ultrasonic stimulation (TUS) is an emerging non-invasive neuromodulation technique with the potential to target both cortical and subcortical brain regions. This study investigates the effects of theta-burst TUS (tb-TUS), a neuromodulatory pattern characterized by bursts of pulses repeated at a theta frequency, on cerebral blood flow, functional connectivity, and metabolite concentrations in the primary motor cortex (M1). The aim of this study is to take a first step towards the mechanistic and methodological feasibility of tb-TUS at the M1 using multimodal neuroimaging. Methods Seventeen healthy participants underwent a double-blind, sham-controlled crossover design, receiving both active and sham tb-TUS to the left M1 over three days. Multimodal MRI, including pseudo-continuous arterial spin labeling (PCASL), resting-state functional MRI (rs-fMRI), and magnetic resonance spectroscopy (MRS), was conducted at baseline, pre-, and post-stimulation. Acoustic simulations and finger-tapping BOLD-peak signal guided individualized TUS targeting. Results Active tb-TUS significantly reduced cerebral blood flow (p < .001) and within-region functional connectivity (p < .001) in the M1 compared to sham stimulation. A non-significant trend towards decreased GABA was observed, with no significant session x condition interaction found for GABA, Glutamate, or Glx concentrations. Conclusion This pilot study demonstrates that tb-TUS of the M1 induces reductions in cerebral blood flow and functional connectivity in healthy participants. Our findings indicate that tb-TUS may be mitigating neural hyperactivity patterns, but preliminary studies so far arrive at differing results, highlighting the need for further research to replicate our findings, elucidate the underlying mechanisms, and optimize stimulation protocols.
Open AccessModulating Brain Perfusion, Functional Connectivity, and Metabolite Patterns through Theta Burst Transcranial Ultrasonic Stimulation
Background Transcranial ultrasonic stimulation (TUS) is an emerging non-invasive neuromodulation technique with the potential to target both cortical and subcortical brain regions. This study investigates the effects of theta-burst TUS (tb-TUS), a neuromodulatory pattern characterized by bursts of pulses repeated at a theta frequency, on cerebral blood flow, functional connectivity, and metabolite concentrations in the primary motor cortex (M1). The aim of this study is to take a first step towards the mechanistic and methodological feasibility of tb-TUS at the M1 using multimodal neuroimaging. Methods Seventeen healthy participants underwent a double-blind, sham-controlled crossover design, receiving both active and sham tb-TUS to the left M1 over three days. Multimodal MRI, including pseudo-continuous arterial spin labeling (PCASL), resting-state functional MRI (rs-fMRI), and magnetic resonance spectroscopy (MRS), was conducted at baseline, pre-, and post-stimulation. Acoustic simulations and finger-tapping BOLD-peak signal guided individualized TUS targeting. Results Active tb-TUS significantly reduced cerebral blood flow (p < .001) and within-region functional connectivity (p < .001) in the M1 compared to sham stimulation. A non-significant trend towards decreased GABA was observed, with no significant session x condition interaction found for GABA, Glutamate, or Glx concentrations. Conclusion This pilot study demonstrates that tb-TUS of the M1 induces reductions in cerebral blood flow and functional connectivity in healthy participants. Our findings indicate that tb-TUS may be mitigating neural hyperactivity patterns, but preliminary studies so far arrive at differing results, highlighting the need for further research to replicate our findings, elucidate the underlying mechanisms, and optimize stimulation protocols.
- Open Access
The Link Between GABA Levels and P300 Abnormalities in Schizophrenia Spectrum Disorders: Regional and Symptom-Based Insights
According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms and particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and are associated with P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P300 amplitudes and latencies, cognition, and symptom severity in SSD. We grouped patients into higher (SSD+) and lower (SSD−) symptom severity clusters based on PANSS total scores. P300 amplitudes were lower in SSD patients than healthy controls at central and parietal sites. SSD+ exhibited widespread reductions at frontal, central, and parietal areas, while SSD− showed reductions limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P300 amplitudes at central and parietal sites within SSD- and overall SSD group. Although P300 amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P300 associations. Our findings suggest P300 amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher disease severity, and that enhanced lDLPFC GABA may help offset these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns mirroring cognitive dysfunction in SSD.
Open AccessThe Link Between GABA Levels and P300 Abnormalities in Schizophrenia Spectrum Disorders: Regional and Symptom-Based Insights
According to the excitation-inhibition imbalance theory, GABAergic and glutamatergic systems influence the clinical symptoms and particularly cognitive deficits in schizophrenia spectrum disorders (SSD). These systems have been found disrupted in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) in SSD, and are associated with P300 abnormalities in electroencephalography recordings. Therefore, we explored the relationships among MRS-derived GABA and Glx levels in the ACC and left DLPFC (lDLPFC), auditory P300 amplitudes and latencies, cognition, and symptom severity in SSD. We grouped patients into higher (SSD+) and lower (SSD−) symptom severity clusters based on PANSS total scores. P300 amplitudes were lower in SSD patients than healthy controls at central and parietal sites. SSD+ exhibited widespread reductions at frontal, central, and parietal areas, while SSD− showed reductions limited to the parietal region. GABA levels in the lDLPFC were higher in SSD− compared to controls and were positively associated with P300 amplitudes at central and parietal sites within SSD- and overall SSD group. Although P300 amplitudes positively correlated with the BACS composite scores and behavioral performance, lDLPFC GABA levels showed no direct association with cognitive or behavioral performance. ACC GABA, ACC Glx, and lDLPFC Glx levels showed no group differences or P300 associations. Our findings suggest P300 amplitude reductions as a marker of cognitive dysfunction in SSD, more pronounced in patients with higher disease severity, and that enhanced lDLPFC GABA may help offset these reductions. Our work provides the first empirical evidence of the interplay between the GABAergic system and cortical electrophysiological signal patterns mirroring cognitive dysfunction in SSD.
- Open Access
Investigation of choroid plexus variability in schizophrenia-spectrum disorders – insights from a multimodal study
Background and Hypothesis Previous studies have suggested that choroid plexus (ChP) enlargement occurs in individuals with schizophrenia-spectrum disorders (SSD) and is associated with peripheral inflammation. However, it is unclear whether such an enlargement delineates a biologically defined subgroup of SSD. Moreover, it remains elusive how ChP is linked to brain regions, associated with peripheral inflammation in SSD. Study Design A cross-sectional cohort of 132 individuals with SSD and 107 age-matched healthy controls (HC) underwent magnetic resonance imaging (MRI) of the brain and clinical phenotyping to investigate the ChP and associated regions. Case-control comparison of ChP volumes was conducted and structural variance was analysed by employing the variability ratio (VR). K-means clustering analysis was used to identify subgroups with distinct patterns of the ventricular system and the clusters were compared in terms of demographic, clinical and immunological variables. The relationship between ChP volumes and brain regions, previously associated with peripheral inflammation, was investigated. Study Results We could not find a significant enlargement of the ChP in SSD compared to HC but detected an increased VR of ChP and lateral ventricle volumes. Based on these regions we identified 3 clusters with differences in age, symbol coding test scores and possibly peripheral neutrophil counts. Larger ChP volume was associated with higher volumes of hippocampus, putamen, and thalamus in SSD, but not in HC. Conclusions This study suggests that ChP variability, but not mean volume, is increased in individuals with SSD, compared to HC. Larger ChP volumes in SSD were associated with higher volumes of regions, previously associated with peripheral inflammation.
Open AccessInvestigation of choroid plexus variability in schizophrenia-spectrum disorders – insights from a multimodal study
Background and Hypothesis Previous studies have suggested that choroid plexus (ChP) enlargement occurs in individuals with schizophrenia-spectrum disorders (SSD) and is associated with peripheral inflammation. However, it is unclear whether such an enlargement delineates a biologically defined subgroup of SSD. Moreover, it remains elusive how ChP is linked to brain regions, associated with peripheral inflammation in SSD. Study Design A cross-sectional cohort of 132 individuals with SSD and 107 age-matched healthy controls (HC) underwent magnetic resonance imaging (MRI) of the brain and clinical phenotyping to investigate the ChP and associated regions. Case-control comparison of ChP volumes was conducted and structural variance was analysed by employing the variability ratio (VR). K-means clustering analysis was used to identify subgroups with distinct patterns of the ventricular system and the clusters were compared in terms of demographic, clinical and immunological variables. The relationship between ChP volumes and brain regions, previously associated with peripheral inflammation, was investigated. Study Results We could not find a significant enlargement of the ChP in SSD compared to HC but detected an increased VR of ChP and lateral ventricle volumes. Based on these regions we identified 3 clusters with differences in age, symbol coding test scores and possibly peripheral neutrophil counts. Larger ChP volume was associated with higher volumes of hippocampus, putamen, and thalamus in SSD, but not in HC. Conclusions This study suggests that ChP variability, but not mean volume, is increased in individuals with SSD, compared to HC. Larger ChP volumes in SSD were associated with higher volumes of regions, previously associated with peripheral inflammation.
- Open Access
- 5 May 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1179811
The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research
Introduction: Treatment of severe mental illness (SMI) symptoms, especially negative symptoms and cognitive dysfunction in schizophrenia, remains a major unmet need. There is good evidence that SMIs have a strong genetic background and are characterized by multiple biological alterations, including disturbed brain circuits and connectivity, dysregulated neuronal excitation-inhibition, disturbed dopaminergic and glutamatergic pathways, and partially dysregulated inflammatory processes. The ways in which the dysregulated signaling pathways are interconnected remains largely unknown, in part because well-characterized clinical studies on comprehensive biomaterial are lacking. Furthermore, the development of drugs to treat SMIs such as schizophrenia is limited by the use of operationalized symptom-based clusters for diagnosis.Methods: In line with the Research Domain Criteria initiative, the Clinical Deep Phenotyping (CDP) study is using a multimodal approach to reveal the neurobiological underpinnings of clinically relevant schizophrenia subgroups by performing broad transdiagnostic clinical characterization with standardized neurocognitive assessments, multimodal neuroimaging, electrophysiological assessments, retinal investigations, and omics-based analyzes of blood and cerebrospinal fluid. Moreover, to bridge the translational gap in biological psychiatry the study includes in vitro investigations on human-induced pluripotent stem cells, which are available from a subset of participants.Results: Here, we report on the feasibility of this multimodal approach, which has been successfully initiated in the first participants in the CDP cohort; to date, the cohort comprises over 194 individuals with SMI and 187 age and gender matched healthy controls. In addition, we describe the applied research modalities and study objectives.Discussion: The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive dysfunction, and treatment-resistant symptoms in general are still difficult to treat.
- 5 May 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1179811
Open AccessThe multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research
Introduction: Treatment of severe mental illness (SMI) symptoms, especially negative symptoms and cognitive dysfunction in schizophrenia, remains a major unmet need. There is good evidence that SMIs have a strong genetic background and are characterized by multiple biological alterations, including disturbed brain circuits and connectivity, dysregulated neuronal excitation-inhibition, disturbed dopaminergic and glutamatergic pathways, and partially dysregulated inflammatory processes. The ways in which the dysregulated signaling pathways are interconnected remains largely unknown, in part because well-characterized clinical studies on comprehensive biomaterial are lacking. Furthermore, the development of drugs to treat SMIs such as schizophrenia is limited by the use of operationalized symptom-based clusters for diagnosis.Methods: In line with the Research Domain Criteria initiative, the Clinical Deep Phenotyping (CDP) study is using a multimodal approach to reveal the neurobiological underpinnings of clinically relevant schizophrenia subgroups by performing broad transdiagnostic clinical characterization with standardized neurocognitive assessments, multimodal neuroimaging, electrophysiological assessments, retinal investigations, and omics-based analyzes of blood and cerebrospinal fluid. Moreover, to bridge the translational gap in biological psychiatry the study includes in vitro investigations on human-induced pluripotent stem cells, which are available from a subset of participants.Results: Here, we report on the feasibility of this multimodal approach, which has been successfully initiated in the first participants in the CDP cohort; to date, the cohort comprises over 194 individuals with SMI and 187 age and gender matched healthy controls. In addition, we describe the applied research modalities and study objectives.Discussion: The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive dysfunction, and treatment-resistant symptoms in general are still difficult to treat.